Johnson & Johnson's Darzalex Q2 sales surpass projections

Coming in over analysts’ expectations, the US-based pharmaceutical giant has booked sales of Darzalex, a cancer drug developed by Genmab, for the year’s second quarter.

Tuesday, Johnson & Johnson publicized its financial figures for the second quarter, and among the US-based firm’s different revenue streams is cancer drug Darzalex, developed by J&J subsidiary Janssen on license from Danish biotech firm Genmab.

During the three-month window, J&J managed to come out on top of analysts’ sales expectations for the drug, according to estimates collected by Bloomberg News.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs